AZD-1940

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
AZD-1940
AZD1940 structure.png
Clinical data
Routes of
administration
Oral
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC20H29F2N3O2S
Molar mass413.53 g·mol−1
3D model (JSmol)

AZD-1940 is a drug developed by AstraZeneca, that is a peripherally selective cannabinoid agonist which binds with high affinity to both the CB1 and CB2 receptors. It was developed for the treatment of neuropathic pain, but while it showed good peripheral selectivity in animal studies,[1] in human clinical trials it failed to show sufficient analgesic efficacy and produced unexpectedly strong side effects associated with central cannabinoid activity, and so was discontinued from further development.[2][3]

See also[edit]

References[edit]

  1. ^ Schou M, Varnäs K, Jucaite A, Gulyás B, Halldin C, Farde L. Radiolabeling of the cannabinoid receptor agonist AZD1940 with carbon-11 and PET microdosing in non-human primate. Nuclear Medicine and Biology, 2013 Apr; 40(3):410-414. doi:10.1016/j.nucmedbio.2012.10.011 PMID 23352602
  2. ^ Kalliomäki J, Segerdahl M, Webster L, Reimfelt A, Huizar K, Annas P, Karlsten R, Quiding H. Evaluation of the analgesic efficacy of AZD1940, a novel cannabinoid agonist, on post-operative pain after lower third molar surgical removal. Scand J Pain. 2013 Jan 1;4(1):17-22. doi:10.1016/j.sjpain.2012.08.004 PMID 29913883
  3. ^ Kalliomäki J, Annas P, Huizar K, Clarke C, Zettergren A, Karlsten R, Segerdahl M. Evaluation of the analgesic efficacy and psychoactive effects of AZD1940, a novel peripherally acting cannabinoid agonist, in human capsaicin‐induced pain and hyperalgesia. Clinical and Experimental Pharmacology and Physiology 2013 Mar; 40(3):212-218. doi:10.1111/1440-1681.12051 PMID 23324098